Table 2 Echocardiographic parameters in aged mice after six weeks of VLDL injection.

From: Very-Low-Density Lipoprotein of Metabolic Syndrome Modulates Gap Junctions and Slows Cardiac Conduction

 

Control (n = 18)

nVLDL (n = 17)

msVLDL (n = 19)

P value

HR (bpm)

425 ± 28

424 ± 46

410 ± 67

0.7243

Measurement (mm)

Ao Root

1.91 ± 0.12

1.99 ± 0.10

1.98 ± 0.14

0.0992

LA

2.15 ± 0.17

2.23 ± 0.25

2.62 ± 0.33

<0.0001¶#

IVSd

1.03 ± 0.16

1.04 ± 0.12

1.03 ± 0.14

0.9307

LVIDd

3.78 ± 0.27

3.90 ± 0.20

4.08 ± 0.46

0.0338

LVPWd

0.93 ± 0.13

0.93 ± 0.16

0.86 ± 0.12

0.2253

LVIDs

2.37 ± 0.33

2.50 ± 0.24

2.79 ± 0.46

0.0038

Calculation

EF (%)

67.6 ± 7.9

66.0 ± 5.8

60.3 ± 7.3

0.0076

FS (%)

37.4 ± 6.2

36.0 ± 4.4

32.0 ± 4.9

0.0093

LV Mass (mg)

142.2 ± 23.6

151.1 ± 23.2

152.6 ± 29.4

0.4372

LVEDV (µL)

61.6 ± 9.7

66.1 ± 8.0

74.5 ± 19.6

0.0222

LVESV (µL)

20.2 ± 6.5

22.6 ± 5.1

30.4 ± 11.9

0.0019¶#

  1. HR, heart rate during the echocardiographic measurement; Ao Root, aortic root diameter; LA, left atrium diameter; IVSd, end-diastolic interventricular septum thickness; LVIDd, end-diastolic LV internal dimension; LVPWd, end-diastolic LV posterior wall thickness; LVIDs, end-systolic LV internal dimension; EF, ejection of fraction; FS, fraction of shortening; LV, left ventricle; LVEDV, LV end-diastolic volume; LVESD, LV end-systolic volume. Comparisons significant for msVLDL vs Control. #Comparison significant for msVLDL vs nVLDL.
Back to article page